Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity

Bibliography

• FRIEDMAN JM: A war on obesity, not the obese. Science (2003) 299:856–859.
   PubMed Web of Science ®Google Scholar
• HILL JO, WYATT HR, REED GW, PETERS JC: Obesity and the environment: where do we go from here? Science (2003) 299:853–855.
   PubMed Web of Science ®Google Scholar
• HANIF MW, KUMAR S: Pharmacological management of obesity. Expert Opin. Phannacother. (2002) 3:1711–1718.
   PubMedGoogle Scholar
• SOJOSTROM L, RISANEN A, ANDERSEN T et al.: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet (1998) 352:167–172.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, HAUPTMAN J DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA (1999) 281:235–242.
   Google Scholar
• HOLLANDER PA, ELBEIN SC, HIRSCH TB et al.: Role of orlistat in the treatment of obese patients with Type 2 diabetes. Diabetes Care (1998) 21:1288–1294.
   PubMed Web of Science ®Google Scholar
• MCNELLYW, GOA KL: Sibutramine in obesity: a review. Drugs (1998) 56:1093–1124.
   PubMed Web of Science ®Google Scholar
• FUJI OKA K, SEATON TB, ROWE E et al.: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. (2000) 2:175–187.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev (2003) 23:146–189.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of CAIs and theirapplications.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. The]: Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. The]: Patents (2002) 12:217–242.
   Web of Science ®Google Scholar
• HEWETT-EMMETT D: Evolution and distribution of the carbonic anhydrase gene families. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Carter N, Edwards Y (E ds), Birkhäuser Verlag, Basel, Switzerland (2000):29–78.
   Google Scholar
• DODGSON SJ: Inhibition of mitochondrial carbonic anhydrase: a discrepancy examined. Appl. Physiol (1987) 63:2134–2141.
   PubMed Web of Science ®Google Scholar
• DODGSON SJ, CHERIAN K: Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis. Am.Physiol (1989) 257:E791–E796.
   Google Scholar
• SPENCER IM, HARGREAVES I, CHEGWIDDEN WR: Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust. Biochem. Soc. Trans. (1988) 16:973–974.
   Web of Science ®Google Scholar
• CHEGWIDDEN WR, SPENCER IM: Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus. Comp. Biochem. Physiol (1996) 115B:247–254.
   Web of Science ®Google Scholar
• CHEGWIDDEN WR, DODGSON SJ, SPENCER IM: The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals. In: The Carbonic Anhydrases - New Horizons Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):343–363.
   Google Scholar
• LYNCH CJ, FOX H, HAZEN SA, STANLEY BA, DODGSON SJ, LANOUE KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. J. (1995) 310:197–202.
   PubMed Web of Science ®Google Scholar
• HAZEN SA, WAHEED A, SLY WS, LANOUE KF, LYNCH CJ: Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J. (1996) 10:481–490.
   PubMed Web of Science ®Google Scholar
• ATWOOD PV: The structure and mechanism of action of pyruvate carboxylase. Int. J. Biochem. Cell Biol. (1995) 27:231–249.
   PubMed Web of Science ®Google Scholar
• ALLDRED JB, REILLY KE: Short-termregulation of acetyl CoA carboxylase in tissues of higher animals. Prog. Lipid Res (1997) 35:371–385.
   Web of Science ®Google Scholar
• FORSTER RE, DODGSON SJ: Membrane transport and provision of substrates for carbonic anhydrase in vertebrates. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):263–280.
   Google Scholar
• PARKKILA S: An overview of the distribution and function of carbonic anhydrase isozymes in mammals. In: The Carbonic Anhydrases - New Horizons. Chegwidden WR, Edwards Y, Carter N (Eds), Birkhäuser Verlag, Basel, Switzerland (2000):79–94.
   Google Scholar
• PARKKILA S, PARKKILA AK, KIVELA J: Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology. In: Carbonic anhydrase, its inhibitors and activators. Supuran CT, Scozzafava A, Conway J (Eds), Taylor & Francis, London & New York (2003) (In Press).
   Google Scholar
• ••Excellent review of CAs ingastroeneterology, neurology and nephrology.
   Google Scholar
• SHAH GN, HEWETT-EMMETT D et al.: Mitochondrial carbonic anhydrase CA VB: differences in tissue distribution and pattern of evolution from those of CA VA suggest distinct physiological roles. Proc. Nat Acad. Sci. USA (2000) 97:1677–1682.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MENABUONI L, MINCIONE F, BRIGANTI F, MINCIONE G, SUPURAN CT: Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action. I Med. Chem. (2000) 43:4542–4551.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, BRIGANTI F, SCOZZAFAVA A: Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J. Enzyme Inhib. (1997) 12:175–190.
   PubMed Web of Science ®Google Scholar
• ILIES M, SUPURAN CT, SCOZZAFAVA A et al.: Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg. Med. Chem. (2000) 8:2145–2155.
   Google Scholar
• ILIES MA, VULLO D, PASTOREK J et al.: Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX with halogenosulfanilamide and halogeno-aminophenylbenzolamide derivatives. Med. Chem. (2003) 46:2187–2196.
   Google Scholar
• SCOZZAFAVA A, MENABUONI L, MINCIONE F, BRIGANTI F, MINCIONE G, SUPURAN CT: Carbonic anhydrase inhibitors: synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?' Med. Chem. (1999) 42:2641–2650.
   Web of Science ®Google Scholar
• SCOZZAFAVA A, BRIGANTIF, MINCIONE G, MENABUONI L, MINCIONE F, SUPURAN CT: Carbonic anhydrase inhibitors: Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. " Med. Chem. (1999) 42:3690–3700.
   PubMed Web of Science ®Google Scholar
• WINUM J-Y, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: Inhibition of cytosolic isozymes I and II and the transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors.' Med. Chem. (2003) 46:2197–2204.
   Web of Science ®Google Scholar
• ••The first comprehensive study oftumour-associated CA IX and its inhibition by sulfarnates.
   Google Scholar
• SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Ept/epsia (1994) 35:450–460.
   PubMed Web of Science ®Google Scholar
• EDMONDS HL, JIANG YD, ZHANG PY, SHANK RP: Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci. (1996) 59:127–131.
   Web of Science ®Google Scholar
• STRINGER JL: A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. (2000) 40:147–153.
   PubMed Web of Science ®Google Scholar
• SABERS A, GRAM L: Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs (2000) 60:23–33.
   PubMed Web of Science ®Google Scholar
• BOURGEOIS BFD: Pharmacokinetics and pharmacodynamics of topiramate. Child Neurol. (2000) 15S27–S30.
   Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res. (2001) 43:11–18.
   PubMed Web of Science ®Google Scholar
• GORDON A, PRICE LH: Mood stabilization and weight loss with topiramate. Am. Psychiatry(1999) 156:968–969.
   PubMed Web of Science ®Google Scholar
• PICARD F, DESHAIES Y, LALONDE J, SAMSON P, RICHARD D: Topiramate reduces energy and fat gains in lean (Fal?) and obese (fa/fa) Zucker rats. Obesity Res. (2000) 8:656–663.
   PubMedGoogle Scholar
• CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841–845.
   PubMed Web of Science ®Google Scholar
• ••Detailed characterisation by means of X-raycrystallography for the adduct of CA II with topiramate, a clinically used drug.
   Google Scholar